Clinical Trials
5
Active:3
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone
Phase 2
Completed
- Conditions
- Hepatitis CHepatocellular CarcinomaHepatitis B
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Mina Alpha Limited
- Target Recruit Count
- 8
- Registration Number
- NCT04710641
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇸🇬National University Hospital Singapore, Singapore, Singapore
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Mina Alpha Limited
- Target Recruit Count
- 50
- Registration Number
- NCT04105335
- Locations
- 🇬🇧
Guys and St Thomas NHS Foundation Trust, London, United Kingdom
🇬🇧Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧Freeman Hospital, Newcastle Upn Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
Phase 1
Active, not recruiting
- Conditions
- Hepatocellular CarcinomaLiver Cancer
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Mina Alpha Limited
- Target Recruit Count
- 75
- Registration Number
- NCT02716012
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇬🇧University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
News
No news found